Sandoz announced the creation of a standalone biosimilars unit led by Armin Metzger, separating biologic follow‑on development, manufacturing and supply from its small‑molecule generics business. The move is designed to streamline decision‑making and capture an anticipated wave of branded biologic patent expirations worth over $650 billion in the next decade. The reshuffle includes executive transitions and redefined leadership roles for generics and biosimilars. Sandoz emphasized that generics remain central to its sales mix but that a focused biosimilars organization will accelerate commercial and technical execution against high‑value biologic opportunities. Investors and competitors will watch how the new unit accelerates biosimilar filings, manufacturing scale‑up, and tender wins across markets facing deep biologic loss of exclusivity.